Search the Newsreel

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

Legend Biotech USA Inc. CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI® availability to 348 global sites and 19 global markets with the launch of Ireland Achieved first clinical proof-of-concept for LB2501, …

Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed

Sana Biotechnology (SANA) reported narrower losses in Q2 2026 and announced a US$25 million equity deal with the Mayo Clinic, contributing to a 13.5% stock increase. The company also made progress in its clinical programs and unveiled promising data for its UP421 cell therapy. …

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage company leveraging its immune medicine platform for diagnostics and treatment, showing a 21.5% revenue growth. Despite current losses and a negative Forward P/E, the company has a strong market capitalization of $4.05 billion and positive analyst sentiment …

Why Did Adaptive Biotechnologies (ADPT) Move After Its Latest Update?

Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com

Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This …

Windlas Biotech Standalone June 2026 Net Sales at Rs 248.10 crore, up 18.09% Y-o-Y

Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Veraxa Biotech AG Ord Shs (VRXA), detailing its future EPS and Revenue Growth Estimates. It includes current stock performance data, market capitalization, and a peer comparison with other biotechnology and medical research companies. The financial forecasting sections …

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIR) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $20.63, significantly higher than its current price of $8.89. The company recently reported strong quarterly earnings, beating revenue and EPS estimates, despite a negative net …

Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Adjusted Net Income $0.16 per Share

Legend Biotech Corporation reported an adjusted net income of $0.16 per share for the second quarter of 2026. This financial announcement was made on August 11, 2026, and also included a reported Q2 revenue of $387.5 million, surpassing FactSet's estimate of $356.0 million. The …

Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Intelligent Protection Management Corp (IPM) Earnings Forecast: Future EPS & Revenue Growth Estimates

CPPLUS Share Price Today - Aditya Infotech Stock Analysis

Hong Kong Market Midday Commentary | All three major indices declined, with the Hang Seng Tech Index down 1.27%; tech and internet stocks fell, with Kuaishou and JD.com each dropping nearly 3%; biotech stocks rose, as GenScript Biotech surged over 8

Sana Biotechnology | 10-Q: Quarterly report

This document is a 10-Q Quarterly Report filed by Sana Biotechnology. It provides a formal financial and operational update for the quarter.

Purple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform

Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech (KRYS) reported strong Q2 2026 results, with net product revenue up 24% to $119.2 million, driven by VYJUVEK sales and expansion into community settings. The company achieved 730+ U.S. reimbursement approvals and is advancing a robust clinical pipeline, including registrational studies for …

If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today

Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an average annual return of 42.63%. An initial investment of $1000 in KRYS five years ago would now be worth $5,893.89, demonstrating the power of compounded returns. The company …

Enterprise value to revenue forward of China Dredging Environment Protection Holdings Limited – HKEX:871

Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-08-10

Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. …

Sana Biotechnology Q2 Results: Adj. EPS beats estimate

Sana Biotechnology reported stronger-than-expected Q2 2026 results, with non-GAAP EPS of $(0.13) surpassing analyst estimates. The company secured $93.3 million in new funding, increasing its cash reserves to $160.5 million and extending its financial runway until mid-2027. This financial stability supports the advancement of …

Sana Biotechnology falls 5% despite beating earnings estimates

Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

Sana Biotechnology (NASDAQ:SANA) reported a quarterly loss of $0.13 per share, surpassing the consensus estimate of a $0.15 loss. Following the announcement, SANA shares increased by 2.6% to $3.61. The company holds a "Moderate Buy" consensus rating from analysts with an average price target …

Sana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary

ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares

A holder of Adaptive Biotechnologies Corp (ADPT) common stock has filed a Form 144, indicating an intention to sell 3,000 shares valued at $74,790.00 through Morgan Stanley Smith Barney. These shares are Restricted Stock Units acquired from the issuer on March 4, 2023. The …

Sana Biotechnology (SANA) warns on going concern amid $110.8M loss

Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12

Sana Biotechnology, Inc. (SANA) reported a Q2 adjusted loss of $0.0.13 per share, which was narrower than the FactSet estimate of a $0.12 loss per share. The company focuses on developing engineered cells as medicines for therapeutic areas such as type 1 diabetes, oncology, …

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for SC451 in type 1 diabetes and SG293 in non-Hodgkin lymphoma, with both expected to start clinical trials this year. The company also announced a follow-on publication in The …

Evotec (NASDAQ:EVO) Shares Gap Up - Here's What Happened

Evotec (NASDAQ:EVO) shares gapped up before the market opened, opening at $2.10 after closing at $2.00, and last traded at $2.0950 on modest volume. Analyst sentiment for the Germany-based biotechnology company is mixed, with a consensus "Hold" rating and a $3.00 average price target, …

Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS

Renaissance Technologies LLC significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 190.9% in the first quarter, now holding 9,600 shares valued at approximately $2.48 million. Other institutional investors have also adjusted their positions, with institutions collectively owning 86.29% of the stock. Analysts …

Evotec and Odyssey Therapeutics team up to accelerate AI-driven drug discovery for autoimmune diseases

Evotec SE and Odyssey Therapeutics have formed a strategic R&D collaboration to accelerate AI-driven drug discovery for autoimmune and inflammatory diseases. The partnership will combine Evotec’s data-driven drug discovery platform, AI-enabled technologies, and screening capabilities with Odyssey’s expertise in disease biology to identify and …

Legend Biotech in spotlight: Earnings test Carvykti momentum

Legend Biotech is set to report its second-quarter earnings, with investors focused on the sustained growth of its CAR-T therapy, Carvykti, amidst increasing competition and a recent CEO departure. Analysts anticipate improved earnings and revenue for the quarter, but concerns linger regarding competitive threats …

Alvotech to Report Financial Results for H1 2026

Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company, announced it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The company will also host a webcast with a live Q&A on Thursday, …

Alvotech Schedules Live Q&A After Its H1 2026 Results Release

Alvotech (NASDAQ: ALVO) will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The company will also host a webcast with a live Q&A session on Thursday, August 20, 2026, at 08:00 ET. …

Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview

Fortress Biotech Inc (FBIO) is expected to report a loss of 20 cents per share in its upcoming earnings. This article is a preview of the company's financial performance.

Legend Biotech (LEGN) CEO Shift: Will CARVYKTI Leadership Rebalance Risk Between Pipeline and Commercial Focus?

Legend Biotech recently announced a leadership change, with CEO Ying Huang stepping down and Alan Bash, President of the CARVYKTI Business Unit, appointed as Interim CEO. This shift places an executive closely associated with the flagship CARVYKTI franchise at the helm, potentially rebalancing the …

Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026)

Veraxa Biotech Holding AG (NASDAQ: VRXA) announced the effectiveness of its F-1 filing with the SEC, dated August 6, 2026, at 4:00 P.M. The filing indicates a neutral impact and sentiment, as analyzed by StockTitan's AI. This notice of effectiveness relates to the company's …